ATE268386T1 - Protease-aktivierbare pseudomonas exotoxin-a- ähnliche proproteine - Google Patents

Protease-aktivierbare pseudomonas exotoxin-a- ähnliche proproteine

Info

Publication number
ATE268386T1
ATE268386T1 AT97947377T AT97947377T ATE268386T1 AT E268386 T1 ATE268386 T1 AT E268386T1 AT 97947377 T AT97947377 T AT 97947377T AT 97947377 T AT97947377 T AT 97947377T AT E268386 T1 ATE268386 T1 AT E268386T1
Authority
AT
Austria
Prior art keywords
domain
proproteins
protease
cysteine
activatable
Prior art date
Application number
AT97947377T
Other languages
English (en)
Inventor
David J Fitzgerald
Yoram Reiter
Ira Pastan
Original Assignee
Nasa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nasa filed Critical Nasa
Application granted granted Critical
Publication of ATE268386T1 publication Critical patent/ATE268386T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97947377T 1996-11-06 1997-11-05 Protease-aktivierbare pseudomonas exotoxin-a- ähnliche proproteine ATE268386T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3037696P 1996-11-06 1996-11-06
PCT/US1997/020207 WO1998020135A2 (en) 1996-11-06 1997-11-05 Protease-activatable pseudomonas exotoxin a-like proproteins

Publications (1)

Publication Number Publication Date
ATE268386T1 true ATE268386T1 (de) 2004-06-15

Family

ID=21853930

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97947377T ATE268386T1 (de) 1996-11-06 1997-11-05 Protease-aktivierbare pseudomonas exotoxin-a- ähnliche proproteine

Country Status (8)

Country Link
US (2) US6426075B1 (de)
EP (1) EP0941334B1 (de)
JP (1) JP2001504334A (de)
AT (1) ATE268386T1 (de)
AU (1) AU716564B2 (de)
CA (1) CA2271291A1 (de)
DE (1) DE69729389D1 (de)
WO (1) WO1998020135A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130160A0 (en) * 1996-12-02 2000-06-01 Univ Wake Forest Inactivation of HIV co-receptors as therapy for HIV infection
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
US7314632B1 (en) * 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
EP1696033A3 (de) * 1997-07-11 2006-12-06 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services Pseudomonas exotoxin-A-ähnliche chimerische Immunogene
EP1000162B1 (de) * 1997-07-11 2006-09-27 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Pseudomonas exotoxin a-ähnliche chimerische immunogene zum auslösen einer sekretorischen iga-vermittelten immunantwort
DK1000163T3 (da) * 1997-07-11 2006-02-06 Us Gov Health & Human Serv Pseudomonas-exotoksin A-lignende kimære immunogener
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US7053042B1 (en) 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
DE60043070D1 (de) * 1999-10-22 2009-11-12 Genentech Inc Proteine-abgabe durch polare epithelzellen schichte
US20030162733A1 (en) * 2000-11-27 2003-08-28 Haynes Joel R. Nucleic acid adjuvants
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
DE60137969D1 (de) 2000-12-21 2009-04-23 Us Gov Health & Human Serv Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält
DE10105912A1 (de) * 2001-02-09 2002-08-14 Roche Diagnostics Gmbh Rekombinante Proteinase K
JP4319908B2 (ja) * 2001-08-24 2009-08-26 ユニバーシティ オブ ビクトリア イノベーション アンド ディベロップメント コーポレーション プロテアーゼ活性化配列を含むプロアエロリシンおよび前立腺癌の治療のための使用方法
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
AU2003207973A1 (en) * 2002-01-31 2003-09-02 Tel Aviv University Future Technology Development L.P. Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20070021345A1 (en) 2003-06-30 2007-01-25 Ehud Gazit Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de) 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
PL2382990T3 (pl) 2003-04-30 2015-04-30 Univ Zuerich Sposoby leczenia raka z zastosowaniem immunotoksyny
US9701725B2 (en) 2003-05-05 2017-07-11 The Johns Hopkins University Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
KR20130065723A (ko) * 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
EP1663199B1 (de) 2003-09-25 2013-04-03 Tel Aviv University Future Technology Development L.P. Zusammensetzungen und diese verwendende verfahren zur behandlung von amyloid-bedingten erkrankungen
WO2005031362A2 (en) 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
EP1694845B8 (de) 2003-11-28 2017-12-20 National Research Council of Canada Antikarzinom-antikörper und verwendungen davon
US8007847B2 (en) 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
EP1781310B1 (de) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Artikel von peptidnanostrukturen und herstellungsverfahren dafür
US7732479B2 (en) 2004-08-19 2010-06-08 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
US20090285771A1 (en) 2004-10-04 2009-11-19 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
AU2005294436A1 (en) * 2004-10-04 2006-04-20 Trinity Biosystems, Inc. Methods and compositions for immunizing against Pseudomonas infection
CA2594040A1 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
JP2008527563A (ja) 2005-01-16 2008-07-24 ズランゴー リミテッド アイコニック通信
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
CA2597638A1 (en) * 2005-02-16 2006-08-24 University Of Zuerich Methods for treating cancer using an immunotoxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer-associated protease site cleaved by mmp-2 or mmp-9
ATE502954T1 (de) * 2005-06-14 2011-04-15 Protox Therapeutics Inc Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine
ES2372537T3 (es) * 2005-07-29 2012-01-23 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Exotoxinas de pseudomonas mutadas con antigenicidad reducida.
ATE518882T1 (de) * 2005-09-19 2011-08-15 Allergan Inc Mit clostridientoxin aktivierbare clostridientoxine
US20070072309A1 (en) * 2005-09-29 2007-03-29 General Electric Company Analytical compositions including nanometer-sized transducers, methods to make thereof, and devices therefrom
EP1973928A2 (de) 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Selbstzusammengebaute fmoc-ff-hydrogele
CA2630559A1 (en) 2005-11-21 2007-05-24 Protox Therapeutics Incorporated Modified pore-forming protein toxins and use thereof
WO2007067597A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
WO2007067596A2 (en) 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
EP1977312A2 (de) 2006-01-16 2008-10-08 Zlango Ltd. Bildzeichenkommunikation
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US8524241B2 (en) * 2007-07-20 2013-09-03 The General Hospital Corporation Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A
WO2009032954A1 (en) * 2007-09-04 2009-03-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
JP2012533587A (ja) * 2009-07-22 2012-12-27 セニックス バイオサイエンス ゲーエムベーハー 自然に存在する細胞内輸送経路を介して化合物を送達するための送達システム及びコンジュゲート
TW201225972A (en) 2010-11-15 2012-07-01 Univ Ramot Dipeptide analogs for treating conditions associated with amyloid fibril formation
US20140065172A1 (en) * 2011-01-26 2014-03-06 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
EP3184547A1 (de) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg-antikörper und verfahren zur verwendung
EP4389913A1 (de) * 2022-12-23 2024-06-26 Universität Heidelberg Pcr-elisa analoges antikörperfreies verfahren zum nachweis einer zielnukleinsäure in einer probe

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US6051405A (en) 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US5082927A (en) 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
US5458878A (en) 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
DK0531434T3 (da) 1990-05-11 2000-01-31 Us Health Forbedrede Pseudomonas-exotoksiner med lav dyretoksicitet og høj cytocidal aktivitet
WO1993025690A1 (en) 1992-06-18 1993-12-23 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant pseudomonas exotoxin with increased activity
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
US6143864A (en) 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides

Also Published As

Publication number Publication date
AU5247498A (en) 1998-05-29
US6426075B1 (en) 2002-07-30
US6423513B1 (en) 2002-07-23
WO1998020135A2 (en) 1998-05-14
EP0941334A2 (de) 1999-09-15
CA2271291A1 (en) 1998-05-14
JP2001504334A (ja) 2001-04-03
WO1998020135A3 (en) 1998-09-11
DE69729389D1 (de) 2004-07-08
EP0941334B1 (de) 2004-06-02
AU716564B2 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
ATE268386T1 (de) Protease-aktivierbare pseudomonas exotoxin-a- ähnliche proproteine
ES2192620T3 (es) Polipeptido receptor de il-13.
AU2001290837A1 (en) Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation
DK0759944T3 (da) Forbedringer af og relateret til peptidfremføring
CA2266316A1 (en) Binary methods of increasing accumulation of essential amino acids in seeds
CO4830493A1 (es) Anticuerpos contra cd40 humano
FI963103A7 (fi) Ei-virusvektori
CY1109978T1 (el) Αντιγονικα πεπτιδια εξαγομενα απο τελομεραση
AU2001271786A1 (en) Interferon-like protein zcyto21
HU9600281D0 (en) Therapeutic peptide derivatives
AU4422797A (en) Methods and compositions for generating angiostatin
EP1350842A3 (de) Rekombinante terminale Deoxynukleotidyltransferase mit verbesserter Funktionalität
GB9305735D0 (en) Novel agent for controlling cell activity
DK0387231T3 (da) Hidtil ukendte inhibitorer for retroviral protease
IL131381A0 (en) Therapeutic agent for lymphatic tumors
PE20010694A1 (es) Plasmido autonomamente reproducible en bacterias corineformes
Bachran et al. Anthrax toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions
DK0953576T3 (da) Aktivt hedgehog-proteinkonjugat, fremgangsmåde til fremstilling heraf og anvendelse
WO2001085777A3 (en) Therapeutic pore-forming peptides
Small et al. Acetylcholinesterase undergoes autolysis to generate trypsin-like activity
DE69500450D1 (de) Verfahren zur Herstellung von D-alpha-Aminosäuren
AU3042497A (en) Vaccine containing a peroxiredoxin and/or a beta-tubulin
EP0794255A3 (de) Verfahren zur Spaltung eines chimeren Proteins mittels eines 'processing'-Enzyms
WO1998046632A3 (de) Inhibitoren für den urokinaserezeptor
Malfroy et al. Purification and substrate specificity of rat kidney “enkephalinase”

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties